Structure-activity relationships of the quinolone antibacterials against mycobacteria: Effect of structural changes at N-1 and C-71

Journal of Medicinal Chemistry

Volumn 39, Issue 3, 1996, Pages 729-735

  Renau, Thomas E ^a   Sanchez, Joseph P ^a   Gage, Jeffrey W ^a   Dever, Julie A ^a   Shapiro, Martin A ^a   Gracheck, Stephen J ^a   Domagala, John M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; LIPOPHILICITY; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; SERODIAGNOSIS; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030041117     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9507082     Document Type: Article

References (40)

1. (a) Cantwell, M. F.; Snider, D. E. Jr.; Cauthen, G. M.; Onorato, I. M. Epidemiology of tuberculosis in the United States, 1985-1992. J. Am. Med. Assoc. 1994, 273, 535-539.
2. (b) Onorato, I. M.; McCray, E. and the Field Services Branch. J. Infec. Dis. 1992, 165, 87-92.
3. (c) Burwen, D. R.; Bloch, A. B.; Griffin, L. D.; Ciesielski, C. A.; Stern, H. A.; Onorato, I. M. National trends in the occurrence of tuberculosis and acquired immunodeficiency syndrome. Arch. Intern. Med. 1995, 155, 1281-1286.
4. Alland, D.; Kalkut, G. E.; Moss, A. R.; McAdam, R. A.; Hahn, J. A ; Bosworth, W.; Drucker, E.; Bloom, B. R. Transmission of tuberculosis in New York city. An analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 1994, 330, 1710-1716.
5. (a) Wallis, R. S.; Vjecha, M.; Amir-Tahmasseb, M.; Okwera, A.; Byekwaso, F.; Nyole, S.; Kabengera, S.; Mugerwa, R. D.; Ellner, J. J. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated β2-microglobulin in HIV-1 associated tuberculosis. J. Infec. Dis. 1993, 167, 43-48.
6. (b) Whalen, C.; Horsburgh, C. R.; Hom, D.; Lahart, C.; Simberkoff, M.; Ellner, J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. 1995, 151, 129-135.
7. (a) Jacobs, R. F. Multiple-drug-resistant tuberculosis. Clin. Infec. Dis. 1994, 19, 1-10.
8. (b) Bloch, A. B.; Cauthen, G. M.; Onorato, I. M.; Dansbury, K. D.; Kelly, G. D.; Driver, C. R.; Snider, D. E. Nationwide survey of drug-resistant tuberculosis in the United States. J. Am. Med. Assoc. 1994, 271, 665-671.
9. Weltman, A. C.; Rose, D. N. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York city hospital. Arch. Intern. Med. 1994, 154, 2161-2167.
10. Houston, S.; Fanning A. Current and potential treatment of tuberculosis. Drugs 1994, 48, 689-708.
11. (a) Gorzynski, E. A. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. Antimicrob. Newslett. 1989, 6, 45-48.
12. (b) Leysen, D. C.; Haemers, A.; Pattyn, S. R. Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. 1989, 33, 1-5.
13. (c) Caekenberghe, D. V. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. J. Antimicrob. Chemother. 1990, 26, 381-386.
14. (d) Berlin, O. G. W.; Young, L. S.; Bruckner, D. A. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 1987, 19, 611-615.
15. (e) Davies, S.; Sparham, P. D.; Spencer, R. C. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J. Antimicrob. Chemother. 1987, 19, 605-609.
16. (f) Karak, K.; De, P. K. Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis. Indian J. Med. Res. 1995, 101, 147-149.
17. Renau, T. E.; Sanchez, J. P.; Shapiro, M. A.; Dever, J. A.; Gracheck, S. J.; Domagala, J. M. Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria. J. Med. Chem. 1995, 38, 2974-2977.
18. Besra, G. S.; Chatterjee D. Lipids and carbohydrates of Mycobacterium tuberculosis. In Tuberculosis; Bloom, B. R., Ed; ASM Press: Washington, DC, 1994; pp 285-306.
19. Sanchez, J. P.; Domagala, J. M.; Hagen, S. E.; Heifetz, C. L.; Hutt, M. P.; Nichols, J. B.; Trehan, A. K. Quinolone antibacterial agents. Synthesis and structure activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J. Med. Chem. 1988, 31, 983-991.
20. Ciba-Geigy A. G. Quinolinecarboxylic acid fungicides. Chem. Abstr. 1979, 90, 163334j.
21. Bouzard, D.; Di Cesare, P.; Essiz, M.; Jacquet, J. P.; Remuzon, P.; Weber, A.; Oki, T.; Masuyoshi M. Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives. J. Med. Chem. 1989, 32, 537-542.
22. Domagala, J. M.; Hagen, S. E.; Joannides, T.; Kiely, J. S.; Laborde, E.; Schroeder, M. C.; Sesnie, J. A.; Shapiro, M. A.; Suto, M. J.; Vanderroest, S. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1-pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy. J. Med. Chem. 1993, 36, 871-881.
23. Lane, C. F. Sodium cyanoborohydride-a highly selective reducing agent for organic functional groups. Synthesis 1975, 135-146.
24. (a) Yung, D. K.; Chatten, L. G.; MacLeod, D. P. Potential antiarrhythmic agents. I. Synthesis and pharmacological evaluation of some piperazine and ethylenediamine analogs of procaine amide. J. Pharm. Sci 1968, 57, 2073-2080.
25. (b) Marsella, J. A. Ruthenium-catalyzed reactions of ethylene glycol with primary amines: steric factors and selectivity control. J. Organomet. Chem. 1991, 407, 97-105.
26. (c) Yamane, T.; Hashizume, T.; Yamashita, K.; Konishi, E.; Hosoe, K.; Hidaka, T.; Watanabe, K.; Kawaharada, H.; Yamamoto, T.; Kuze, F. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. 1993, 41, 148-155.
27. Grohe, K.; Heitzer, H. Cycloaracylierung von enaminen, I. Synthese von 4-chinolon-3-carbonsaueren. Liebigs Ann. Chem. 1987, 29-37.
28. 1-substituent in determining the structure-activity relationship. J. Med. Chem. 1991, 34, 1142-1154.
29. Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Pihuleac, E.; Nordeen, C. W.; Maleczka, R. E., Jr.; Pernet, A. G. Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J. Med. Chem. 1985, 28, 1558-1564.
30. Narita, H.; Konishi, Y.; Nitta, J.; Nagaki, H.; Kobayashi, Y.; Watanabe, Y.; Minami, S.; Saikawa, I. Pyridonecarboxylic acids as antibacterial agents. IV. Synthesis and structure-activity relationship of 7-amino-1-aryl-6-fluoro-4-quinolone-3-carboxylic acids. Yakugaku Zasshi 1986, 106, 795-801.
31. Hagen, S. H.; Domagala, J. M.; Heifetz, C. L.; Johnson, J. Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids. J. Med. Chem. 1991, 34, 1155-1161.
32. Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem. 1980, 23, 1358-1363.
33. Domagala, J. M.; Heifetz, C. L.; Mich, T. F.; Nichols, J. B. 1-ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4- oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent Gram-positive activity. J. Med. Chem. 1986, 29, 445-448.
34. Bouzard, D.; Di Cesare, P.; Essiz, M.; Jacquet, J. P.; Kiechel, J. R.; Remuzon, P.; Weber, A.; Oki, T.; Masuyoshi, M.; Kessler, R. E.; Fung-Tomc, J.; Desiderio, J. Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives. J. Med. Chem. 1990, 33, 1344-1352.
35. National Committee for Clinical Laboratory Standards. Methods for dilution susceptibility tests for bacteria that grow aerobically, 3rd ed.; antimicrobial approved standard; NCCLS publication M7-A3: Villanova, PA, April 1993.
36. Cohen, M. A.; Griffin, T. J.; Bien, P. A.; Heifetz, C. L.; Domagala, J. M. In vitro activity of CI-934, a quinolone carboxylic acid active against gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 1985, 28, 766-772.
37. Chu, D. T. W.; Fernandes, P. B. Recent developments in the field of quinolone antibacterial agents. In Advances in Drug Research; Testa, B., Ed.; Academic Press: New York, 1991; pp 39-144.
38. Haemers, A.; Leysen, D. C.; Bollaert, W.; Zhang, M.; Pattyn, S. R. Influence of N substitution on antimycobacterial activity of ciprofloxacin. Antimicrob. Agents Chemother. 1990, 34, 496-497.
39. Heifets, L. B.; Good, R. C. Current laboratory methods for the diagnosis of tuberculosis. In Tuberculosis; Bloom, B. R., Ed.; ASM Press: Washington, DC, 1994; pp 85-110.
40. Domagala, J. M. Structure-activity side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685-706.